Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q1 2024
Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.
- Positions
- 65
- +21 vs. Q4 2023
- Portfolio value
- $311.1M
- +$137.3M (+79.1%) vs. Q4 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| NTLAIntellia Therapeutics, Inc. | COM | 25,000 | $687.8K | 0.2% | +25,000 | New | History |
| ANTXAN2 Therapeutics, Inc. | COM | 219,331 | $712.8K | 0.2% | +219,331 | New | History |
| QUREuniQure N.V. | SHS | 165,000 | $858.0K | 0.3% | 00.0% | Unchanged | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 20,000 | $933.8K | 0.3% | +20,000 | New | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 35,000 | $1.00M | 0.3% | +35,000 | New | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 675,000 | $1.15M | 0.4% | −50,000−6.9% | Reduced | History |
| ATYRaTYR PHARMA INC | COM NEW | 600,000 | $1.17M | 0.4% | +600,000 | New | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 225,000 | $1.22M | 0.4% | +225,000 | New | History |
| NGNENeurogene Inc. | COM | 25,000 | $1.27M | 0.4% | +25,000 | New | History |
| ELEVElevation Acquisition Group Inc. | COM | 250,000 | $1.28M | 0.4% | +250,000 | New | History |
| CTMXCytomX Therapeutics, Inc. | COM | 600,000 | $1.31M | 0.4% | +600,000 | New | History |
| CYTKCytokinetics Inc | COM NEW | 20,000 | $1.40M | 0.5% | +10,000+100.0% | Added | History |
| LRMRLarimar Therapeutics, Inc. | COM | 210,603 | $1.60M | 0.5% | +210,603 | New | History |
| ATXSAstria Therapeutics, Inc. | COM | 115,000 | $1.62M | 0.5% | −220,000−65.7% | Reduced | History |
| ARVNArvinas, Inc. | COM | 40,000 | $1.65M | 0.5% | −19,250−32.5% | Reduced | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 6,500 | $1.74M | 0.6% | −8,500−56.7% | Reduced | History |
| EYPTEyePoint, Inc. | COM NEW | 90,000 | $1.86M | 0.6% | −75,000−45.5% | Reduced | History |
| PTGXProtagonist Therapeutics, Inc | COM | 75,000 | $2.17M | 0.7% | −50,000−40.0% | Reduced | History |
| RVNCRevance Therapeutics, Inc. | COM | 450,000 | $2.21M | 0.7% | +75,000+20.0% | Added | History |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | COM NEW | 56,941 | $2.23M | 0.7% | +56,941 | New | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 200,000 | $2.26M | 0.7% | +200,000 | New | History |
| NTRANatera, Inc. | COM | 25,000 | $2.29M | 0.7% | −10,000−28.6% | Reduced | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 200,000 | $2.37M | 0.8% | +69,964+53.8% | Added | History |
| KRYSKrystal Biotech, Inc. | COM | 14,000 | $2.49M | 0.8% | −36,000−72.0% | Reduced | History |
| RGNXREGENXBIO Inc. | COM | 120,000 | $2.53M | 0.8% | +120,000 | New | History |
| ALTAltimmune, Inc. | COM NEW | 250,000 | $2.54M | 0.8% | +250,000 | New | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 285,000 | $2.58M | 0.8% | +150,000+111.1% | Added | History |
| GERNGeron Corp | COM | 800,000 | $2.64M | 0.8% | +800,000 | New | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 950,000 | $2.73M | 0.9% | −1,150,000−54.8% | Reduced | History |
| DCPHDeciphera Pharmaceuticals, Inc. | COM | 176,513 | $2.78M | 0.9% | −48,487−21.5% | Reduced | History |
| AQSTAquestive Therapeutics, Inc. | COM | 702,941 | $2.99M | 1.0% | +702,941 | New | History |
| COGTCogent Biosciences, Inc. | COM | 450,000 | $3.02M | 1.0% | +255,000+130.8% | Added | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 300,000 | $3.12M | 1.0% | +300,000 | New | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 75,000 | $3.21M | 1.0% | −75,000−50.0% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 75,000 | $3.29M | 1.1% | +75,000 | New | History |
| ENGNenGene Therapeutics Inc. | COM | 200,000 | $3.39M | 1.1% | +200,000 | New | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 150,000 | $3.57M | 1.1% | +150,000 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 100,000 | $3.79M | 1.2% | +100,000 | New | History |
| IMVTImmunovant, Inc. | COM | 125,000 | $4.04M | 1.3% | +125,000 | New | History |
| TNYATenaya Therapeutics, Inc. | COM | 775,000 | $4.05M | 1.3% | +775,000 | New | History |
| INSMINSMED Inc | COM PAR $.01 | 150,000 | $4.07M | 1.3% | +150,000 | New | History |
| ACADAcadia Pharmaceuticals Inc | COM | 225,000 | $4.16M | 1.3% | +175,000+350.0% | Added | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 485,000 | $5.15M | 1.7% | +99,759+25.9% | Added | History |
| REPLReplimune Group, Inc. | COM | 650,000 | $5.31M | 1.7% | +250,000+62.5% | Added | History |
| BBIOBridgeBio Pharma, Inc. | COM | 175,000 | $5.41M | 1.7% | +50,000+40.0% | Added | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 125,000 | $5.42M | 1.7% | +125,000 | New | History |
| VKTXViking Therapeutics, Inc. | COM | 73,002 | $5.99M | 1.9% | +73,002 | New | History |
| CABACabaletta Bio, Inc. | COM | 375,000 | $6.40M | 2.1% | +225,000+150.0% | Added | History |
| PCVXVaxcyte, Inc. | COM | 95,000 | $6.49M | 2.1% | +25,000+35.7% | Added | History |
| JBIOJade Biosciences, Inc. | COM | 225,000 | $6.65M | 2.1% | +15,000+7.1% | Added | History |
| BPMCBlueprint Medicines Corp | COM | 72,761 | $6.90M | 2.2% | +72,761 | New | History |
| CATXPerspective Therapeutics, Inc. | COM | 6,000,000 | $7.14M | 2.3% | +4,400,000+275.0% | Added | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 130,000 | $7.64M | 2.5% | +130,000 | New | History |
| SVRASavara Inc | COM | 1,600,000 | $7.97M | 2.6% | +850,000+113.3% | Added | History |
| SLNOSoleno Therapeutics Inc | COM | 200,000 | $8.56M | 2.8% | +87,615+78.0% | Added | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 60,000 | $8.97M | 2.9% | +32,500+118.2% | Added | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 200,000 | $9.36M | 3.0% | +135,000+207.7% | Added | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 300,000 | $10.9M | 3.5% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 625,000 | $10.9M | 3.5% | +325,000+108.3% | Added | History |
| TGTXTG Therapeutics, Inc. | COM | 825,000 | $12.5M | 4.0% | +575,000+230.0% | Added | History |
| ROIVRoivant Sciences Ltd. | SHS | 1,300,000 | $13.7M | 4.4% | +700,000+116.7% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 300,000 | $15.1M | 4.8% | +220,000+275.0% | Added | History |
| BHVNBiohaven Ltd. | COM | 285,000 | $15.6M | 5.0% | +10,000+3.6% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 125,000 | $16.2M | 5.2% | +25,000+25.0% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 210,000 | $16.8M | 5.4% | +45,000+27.3% | Added | History |
Options (7)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| State Street SPDR S&P Biotech ETF78464A870 | ETF | $23.7M | – |
| VKTXViking Therapeutics, Inc. | COM | – | $6.56M |
| CYTKCytokinetics Inc | COM NEW | – | $5.26M |
| IMVTImmunovant, Inc. | COM | – | $4.85M |
| ACADAcadia Pharmaceuticals Inc | COM | – | $3.70M |
| ITCIIntra-Cellular Therapies, Inc. | COM | – | $3.46M |
| RAPTRAPT Therapeutics, Inc. | COM | – | $2.69M |
Sold out since Q4 2023 (7)
Positions held at the end of Q4 2023 that are gone from this filing.
| Security | Class | Shares in Q4 2023 | Value in Q4 2023 | % of portfolio in Q4 2023 | History |
|---|---|---|---|---|---|
| AMAMAmbrx Biopharma, Inc. | COM | 475,000 | $6.76M | 3.9% | History |
| ARGXArgenx SE | SPONSORED ADR | 15,000 | $5.71M | 3.3% | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 20,000 | $2.52M | 1.5% | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 90,000 | $2.13M | 1.2% | History |
| INBXInhibrx Biosciences, Inc. | COM | 35,000 | $1.33M | 0.8% | History |
| BLUEbluebird bio, Inc. | COM | 465,000 | $641.7K | 0.4% | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 30,000 | $596.4K | 0.3% | History |